慣性聚合 高效追蹤和閱讀你感興趣的部落格、新聞、科技資訊
閱讀原文 在慣性聚合中打開

推薦訂閱源

小众软件
小众软件
博客园 - 叶小钗
有赞技术团队
有赞技术团队
大猫的无限游戏
大猫的无限游戏
博客园_首页
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
L
LangChain Blog
Hugging Face - Blog
Hugging Face - Blog
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
aimingoo的专栏
aimingoo的专栏
Blog — PlanetScale
Blog — PlanetScale
爱范儿
爱范儿
T
Tailwind CSS Blog
Jina AI
Jina AI
量子位
Stack Overflow Blog
Stack Overflow Blog
人人都是产品经理
人人都是产品经理
J
Java Code Geeks
V
Visual Studio Blog
月光博客
月光博客

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem CuriosityStream: AI Is Not Enough For An Investment Here Akamai Collapse: Did Anthropic Just Kill Its Prospects? I Think Not Potential $5,000 Monthly Income - 12 Investments To Buy And Hold For The Next 10 Years Citizens Financial Group: Q1 Results Should Validate Recent Strength Weekly Indicators: The Consumer Continues To Spend Like There's No Tomorrow Don't Overlook Arthur J. Gallagher & Co. When Investing Global Ship Lease: Embedded Upside From Charter Repricing And Trade Disruption Marvell: Rating Upgrade On Data Center Boom EMCOR Group: Solid Business That Is Fully Valued High-Yield REITs I Would Trust For Retirement Income Rubrik's Growth Engines Are Working, But 18% Dilution Risk Weighs On The Upside Coeur Mining: The Market Is Still Pricing The Old CDE Morgan Stanley Direct Lending Has Some Issues, But The Price Makes It Buyable Exploring Digital Equity With These 3 Stocks Twin Disc's Pop Means It's Time For A Downgrade Peloton: Great Improvements But With An Idea Lacking Evidence Tap The Brakes And Buy SPLV Clean Up Your Portfolio With Bath & Body Works Devon-Coterra Merger: Good And Bad Tyson Foods: Pivoting Beyond Cyclicality Into Structural Growth
Nykode Therapeutics AS (VACBF) 2026年第一季度盈利電話會議文字記錄
2026-05-28 · via All Articles on Seeking Alpha

Nykode Therapeutics AS (VACBF) Q1 2026 獲利電話會議 2026年5月27日 上午9:00 ETD

公司參與人員

Michael Engsig - 首席執行官
Agnete Fredriksen - 創辦人之一& 首席科學官
Harald Gurvin - 首席財務官

演講

操作員

您好,歡迎來到 Nykode Therapeutics Q1 2026 財務結果發布會。[操作員指示]。請注意,本次會議正被錄製。

現在,我很榮幸將會議交給 Nykode 的執行長,Michael Engsig。請開始,先生。

Michael Engsig
執行長

非常感謝您,Kevin。同時,由我這邊來說,也熱烈歡迎所有聽眾參加我們在奧斯陸這個美麗夏日舉行的首季網絡直播。快速看一下我們的未來展望聲明,我想您們都相當熟悉。基於這一點,我們將繼續前進。照例,今天能與我一起在這裡,我感到非常榮幸。Agnete Fredriksen,我們的共同創辦人、首席科學官和業務發展主管;以及 Harald Gurvin,我們的首席財務官。我們將為您帶來本季的重點,稍微深入探討一些數據,當然,還有財務數字。

所以對於新的聽眾,我會非常快速地回顧一下。Nykode 是一家臨床階段的免疫療法公司,專注於利用我們的抗原呈遞細胞靶向免疫療法平台,在癌症和自身免疫性疾病領域發現新的免疫療法。我們的領先資產是 abi-suva,我們正在第一線頭頸癌中開發它。但我也對 VB10.NEO 非常有信心,這是我們的個性化新抗原療法平台以及我們的自身免疫性疾病計劃。我們資金充裕,資金將我們帶到 2028 年,這是在所有重要轉折點的另一邊。這是一個忙碌的季度,在許多方面都有很多進展——特別是在 abi-suva 上,但在我們的其他計劃上也有有趣的發展。對於 abi-suva,我們給了第一個